These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 10853862

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacological treatment of the ion transport defect in cystic fibrosis.
    Roomans GM.
    Expert Opin Investig Drugs; 2001 Jan; 10(1):1-19. PubMed ID: 11116277
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR.
    Rubenstein RC, Egan ME, Zeitlin PL.
    J Clin Invest; 1997 Nov 15; 100(10):2457-65. PubMed ID: 9366560
    [Abstract] [Full Text] [Related]

  • 9. A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator delta F508 mutation.
    Guay-Broder C, Jacobson KA, Barnoy S, Cabantchik ZI, Guggino WB, Zeitlin PL, Turner RJ, Vergara L, Eidelman O, Pollard HB.
    Biochemistry; 1995 Jul 18; 34(28):9079-87. PubMed ID: 7542476
    [Abstract] [Full Text] [Related]

  • 10. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function.
    Rubenstein RC, Zeitlin PL.
    Am J Respir Crit Care Med; 1998 Feb 18; 157(2):484-90. PubMed ID: 9476862
    [Abstract] [Full Text] [Related]

  • 11. Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein.
    Illek B, Zhang L, Lewis NC, Moss RB, Dong JY, Fischer H.
    Am J Physiol; 1999 Oct 18; 277(4):C833-9. PubMed ID: 10516113
    [Abstract] [Full Text] [Related]

  • 12. Novel amino-carbonitrile-pyrazole identified in a small molecule screen activates wild-type and ΔF508 cystic fibrosis transmembrane conductance regulator in the absence of a cAMP agonist.
    Namkung W, Park J, Seo Y, Verkman AS.
    Mol Pharmacol; 2013 Sep 18; 84(3):384-92. PubMed ID: 23788656
    [Abstract] [Full Text] [Related]

  • 13. Correction of G551D-CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07.
    Zegarra-Moran O, Romio L, Folli C, Caci E, Becq F, Vierfond JM, Mettey Y, Cabrini G, Fanen P, Galietta LJ.
    Br J Pharmacol; 2002 Oct 18; 137(4):504-12. PubMed ID: 12359632
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR.
    Rubenstein RC, Zeitlin PL.
    Am J Physiol Cell Physiol; 2000 Feb 18; 278(2):C259-67. PubMed ID: 10666020
    [Abstract] [Full Text] [Related]

  • 16. DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers.
    Rowe SM, Pyle LC, Jurkevante A, Varga K, Collawn J, Sloane PA, Woodworth B, Mazur M, Fulton J, Fan L, Li Y, Fortenberry J, Sorscher EJ, Clancy JP.
    Pulm Pharmacol Ther; 2010 Aug 18; 23(4):268-78. PubMed ID: 20226262
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.